Hormone Sensitive Metastatic Disease: Tumor Boards

This is a case-based activity that includes discussion of a 36-year-old woman who originally presented at 18 weeks gestation with clinical T2N0, grade 3 invasive ductal carcinoma of the right breast. The tumor was ER+, PR+, and HER2 negative.

Learning Objectives

  • Explain how to incorporate recent evidence-based guideline recommendations and new data to select first-line therapy for women with hormone sensitive advanced breast cancer
  • Describe the evolving role of ovarian suppression in the treatment of premenopausal women with early or advanced hormone sensitive breast cancer

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Notes

  • This course expires on October 28, 2019. Participants must complete all necessary course components by this date.
  • This course is available as part of the 2016 ASCO Tumor Boards bundle.